

28 January 2025

Page: 1/2

(25-0670) Committee on Technical Barriers to Trade

Original: English

NOTIFICATION

Addendum

The following communication, dated 28 January 2025, is being circulated at the request of the delegation of the <u>United States of America</u>.

Title: Nonprescription Drug Product With an Additional Condition for Nonprescription Use

Reason for Addendum:	
[]	Comment period changed - date:
[]	Notified measure adopted - date:
[]	Notified measure published - date:
[X]	Notified measure enters into force - date: 21 March 2025; The effective date for the final rule published 26 December 2024, (89 FR 105288), is delayed until 21 March 2025.
[X]	Text of final measure available from ¹ :
	https://www.govinfo.gov/content/pkg/FR-2024-12-26/html/2024-30261.htm
	https://www.govinfo.gov/content/pkg/FR-2024-12-26/pdf/2024-30261.pdf
[]	Notified measure withdrawn or revoked - date:
	Relevant symbol if measure re-notified:
[]	Content or scope of notified measure changed and text available from ¹ :
	New deadline for comments (if applicable):
[]	Interpretive guidance issued and text available from ¹ :
[X]	Other:
	The effective date for the final rule published 26 December 2024, (89 FR 105288), is delayed until 21 March 2025.
	https://members.wto.org/crnattachments/2025/TBT/USA/25_00971_00_e.pdf

Description: In accordance with the memorandum of 20 January 2025, from the President, entitled "Regulatory Freeze Pending Review," the effective date of the <u>final rule</u>, (notified as <u>G/TBT/N/USA/1889/Add.2</u>) entitled Nonprescription Drug Product With an Additional Condition for Nonprescription Use," (ACNU) is delayed until 21 March 2025.

The effective date for the final rule published 26 December 2024, (<u>89 FR 105288</u>), is delayed until 21 March 2025.

¹ This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained.

90 Federal Register (FR) 8173, 27 January 2025; <u>Title 21</u> Code of Federal Regulations (CFR) Parts <u>201</u> and <u>314</u>:

https://www.govinfo.gov/content/pkg/FR-2025-01-27/html/2025-01840.htm

https://www.govinfo.gov/content/pkg/FR-2025-01-27/pdf/2025-01840.pdf

This action and previous actions notified under the symbol <u>G/TBT/N/USA/1889</u> are identified by Docket Number FDA-2021-N-0862. The Docket Folder is available from Regulations.gov at <u>https://www.regulations.gov/docket/FDA-2021-N-0862/document</u> and provides access to primary and supporting documents as well as comments received. Documents are also accessible from <u>Regulations.gov</u> by searching the Docket Number.